FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.	APPLICATION NO.
202.2D6	10/741,929
APPLICANT: Clarence N. Ahlem, et al	
FILING DATE: December 19, 2003	GROUP: 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BB		2,878,267	05/17/59	Szpilfogel et al			
		5,567,695	10/22/96	Labrie			
		5,763,433	06/09/98	Morfin			
		5,776,923	07/07/98	Labrie			
		5,837,269	11/17/98	Daynes et al.			
BB		6,077,873	06/20/00	Loozen			2/19/98

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME AND PORTIONS OF DOCUMENT	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		US 2005/0075321 A1	Ahlem et al., first page and pages 102-107 (claims)			
		US 2004/0043973 A1	Ahlem et al., first page and pages 99-101 (claims)			
		US 2003/0119800 A1	Manolagas et al., entire document			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
BB		EP 0 429 187 B1	05/01/94	Europe				
		EP 0 289 327 A	11/02/88	Europe				
		EP 01 133 995 A2	08/02/83	Europe				
BB		DE 38 12 595 C2	10/27/88	Germany			X	

EXAMINER	DATE CONSIDERED
Badio	9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BB		Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehyroepiandrosterone sulphate (DHEAS), *Immunology* 90:344-349 (1997)
		Araghi-Niknam et al., Cytokine Dysregulation and Increased Oxidation IS Prevented by Dehydroepiandrosterone in Mice Infeced with Murine Leukemia Retrovirus, *Proc. Soc. Exp. Biol. Med.* 216(3):386-391 (1997)
		B. F. Bebo et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, *J. Immunol.* 162:35-40 1999
		Henderson et al., Dehydroepiandrosterone and 16α-bromoepiandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, *Carcinogenesis*, 2(7), pp. 683-686 1981
		Hernandez-Pando et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, *Immunology* 95(2):234-241 1998
		P. Inserra et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, *Proc. Soc. Exp. Biol. Med.* 218:76-82 1998
		Kang et al., Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Taehan Misaengmulhak Hoechi (J. Korean Soc. Microbiology)* 31(4):399-404 (1996) (translation from Korean)
		Kang et al, Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Chem Abstracts 2-Mammalian Hormones* 126(9) pp. 99 (Abstract 113406a)
		Kousteni S, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids, *Science* 298:843-846 2002
		Manz et al., Methyl 17ß-Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, *J. Clin. Chem. Clin. Biochem.* 21(2):69-75 (1983)
		Sigg et al., Methyl 3α-acetoxyetien-(8:9 or 8:14)-ate, Preliminary Communication, Helvetica Chimica Acta, 39:1507-1525 1956 (translation from German)
		Xia P, et al. Anti-Aids agents. Part 36: 1 17-carboxylated steroids as potential anti-HIV agents, *BIOORG Med. Chem* 7(9), pp. 1907-1911 (Sep 1999)
		Yang et al., Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, *Aids Research and Human Retroviruses* 9(8):747-754 (1993)
BB		Z. Zhang et al., Prevention if immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, *Immunology* 96:291-297 1999

EXAMINER	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE December 19, 2003	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
BB		H6-279488	10-04-94	Japan	---	---	X	

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BB	✓	Bruder, S. P., et al., Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy, *J Cell Biochem*, 56(3), pp. 283-94, 1994
	✓	Chen, Z.et al., Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J. Clin. Invest.* 103, pp. 401-406, 1999
	✓	Fink, B. E. et al., Novel structural templates for estrogen-receptor ligands and Prospects for Combinatorial Synthesis of Estrogens. *Chem. Biol.*, 6, pp. 205-219,1999
		Gao, H. et al., Comparative QSAR analysis of estrogen receptor ligands, *Chem. Rev.*, 99, pp. 723-744, 1999
		Grundy, J., Artificial Estrogens. The Technical College, Acton, London, W.S., England, pp.281-416, May 1956
BB		Jilka RL, et al., Increased osteoclast development after estrogen loss: mediation by interlekin-6, *Science* 257, pp. 88-91, 1992

EXAMINER Badio	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BB		Jilka, R.L. et al., Increased bone formation by prevention of osteoblast apoplosis with parathyroid hormone, *Journal of Clinical Investigation*, 104(4), pp 439-446 August 1999.
		Khosla, S. et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. *J. Clin. Endocrinol. Metab.* 83, pp. 2266-2274, 1998
		Lea, C.K. et al., Androstenedione treatment reduces loss of cancellous bone volume in ovariectomized rats in a dose-responsive manner and the effect is not mediated by estrogen, *J. Endocrinol.*, 156, pp. 331-339, 1988
		Ojasoo, T. and Raynaud, J. P. Unique steroid congeners and receptors studies, *Cancer Res.*, 38, pp. 4186-4198, 1978
		Oursler M. J., Estrogen regulation of gene expression in osteoblasts and osteoclasts *Critical Review in Eucaryotic Gene Expression*, 8:125-140 1998
		Picherit, C. et al., Dihydrotesterone prevents glucocorticoid-negative effects on fetal rat metatarsal bone *in vitro*, *Biol. Neonate*, 77:181-190 2000
		Pietras, R.J. and C.M.Szego. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. *Nature*, 265, pp.69-72, 1977
		Plotkin, L.I., et al., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, *J. Clin. Invest.* 104(10):1363-1374 November 1999.
		Pomper, M. G., et al., 11β-Methoxy-, 11β-ethyl- and 17α-ethynyl-substituted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. *J. Med. Chem.*, 33, pp. 3143-3155, 1990
		Riggs, B, et al. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis, *J. Clin. Invest.*, 51, pp.1659-1663, 1972
		Santoro, N.F., et al, Therapeutic controversy: Hormone replacement therapy-where are we going? *J. Clin. Endocrinol. Metab.* 84, pp.1798-1812, 1999
		Scheven B.A., et al, Dehydroepiandrosteone (DHEA) and DHEA-S interact with 1,25-dihydroxyvitamin D_3 ($1,25(OH)_2D_3$) to stimulate human osteoblastic cell differentiation Life Sciences, 62, pp. 59-68, 1988
BB		Solmssen, U. V., Synthetic estrogens and the relation between their structure and their activity. *Chem. Res.*, 37, pp. 481-598, 1945
		Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7α,11β-Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. Bioorg. Med. Chem. Lett., 7, 2919-2924 1997 Copy needed
		Tobias, J.H., et al., 5α-dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, *Am. J. Physiol. Endocrinol. Metab.* 267, pp. E853-E859, 1994. Copy needed
BB		Watts, N. B., Clinical utility of biochemical markers of bone remodeling, *Clin. Chem.*, 45, pp. 1359-1368, 1999
		Weinstein R.S. et al., Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids *J. Clin.Invest.* 102, pp. 274-282, 1998
BB		Weinstein RS et al., The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage, *Endocrinology* 138, pp. 4013-4021, 1997

EXAMINER	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE December 19, 2003	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BB	1	2,843,608	07-15-58	Colton			
	2	2,843,609	07-15-58	Colton			
	3	4,069,321	01-17-78	Jones et al.			
	4	5,011,678	04-30-91	Wang et al.			
	5	5,116,828	05-26-92	Miura et al.			
	6	5,162,312	11-10-92	Kasch et al.			
	7	5,183,815	02-02-93	Saari et al.			
	8	5,565,444	10-15-96	Mitzushima et al.			
	9	5,795,883	08-18-83	Hesch et al.			
	10	5,817,816	10-06-98	Harimaya et al.			
	11	5,837,700	11-17-98	Labrie			
	12	5,843,934	12-01-98	Simpkins			
	13	5,846,960	12-08-98	Labrie			
	14	5,880,117	03-03-99	Arnold			
	15	6,011,026	01-04-00	Bouali et al.			
	16	6,011,027	01-04-00	Arnold			
	17	6,313,180 B1	11-06-01	Loozen			
BB	18	6,667,299 B1	12-23-03	Ahlem et al.			

EXAMINER	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE December 19, 2003	GROUP 1617

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	19	US 2005/0101581 A1	Ahlem et al.			
	20	US 2005/0026223 A1	Manolagas et al.			
	21	US 2004/0248078 A1	Manolagas et al.			
	22	US 2004/0220114 A1	Ahlem et al.			
	23	US 2004/0224884 A1	Manolagas et al.			
	24	US 2004/0138187 A1	Ahlem et al.			
	25	US 2004/0157812 A1	Labrie			
	26	US 2004/0116359 A1	Ahlem et al.			
	27	US 2004/0097406 A1	Ahlem et al.			
	28	US 2003/0225046 A1	Liao et al.			
	29	US 2003/0083231 A1	Ahlem et al.			
	30	US 2003/0060425 A1	Ahlem et al.			
	31	US 2002/0187970 A1	Labrie			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BB	32	WO 00/20007	04-13-00	PCT				
	33	WO 99/61044	12-02-99	PCT				
	34	WO 99/63973	12-16-99	PCT				
	35	WO 98/56386	12-17-98	PCT				
BB	36	WO 93/10141	05-27-93	PCT				

EXAMINER Badio	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE)
BB	37	Karsenty, The genetic transformation of bone biology, *Genes & Development*, 13:3037-3051 1999
BB	38	Slemenda et al., Sex steroids, bone mass and bone losss, *J. Clinical Invest.*, 97:14-21 1996

EXAMINER Badea	DATE CONSIDERED 9/13/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.